193 related articles for article (PubMed ID: 21220050)
1. Pharmacokinetics and biodistribution of lonidamine/paclitaxel loaded, EGFR-targeted nanoparticles in an orthotopic animal model of multi-drug resistant breast cancer.
Milane L; Duan ZF; Amiji M
Nanomedicine; 2011 Aug; 7(4):435-44. PubMed ID: 21220050
[TBL] [Abstract][Full Text] [Related]
2. Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells.
Milane L; Duan Z; Amiji M
Mol Pharm; 2011 Feb; 8(1):185-203. PubMed ID: 20942457
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer.
Milane L; Duan Z; Amiji M
PLoS One; 2011; 6(9):e24075. PubMed ID: 21931642
[TBL] [Abstract][Full Text] [Related]
4. Biodistribution and pharmacokinetic analysis of Paclitaxel and ceramide administered in multifunctional polymer-blend nanoparticles in drug resistant breast cancer model.
van Vlerken LE; Duan Z; Little SR; Seiden MV; Amiji MM
Mol Pharm; 2008; 5(4):516-26. PubMed ID: 18616278
[TBL] [Abstract][Full Text] [Related]
5. Reversal of multidrug resistance by co-delivery of paclitaxel and lonidamine using a TPGS and hyaluronic acid dual-functionalized liposome for cancer treatment.
Assanhou AG; Li W; Zhang L; Xue L; Kong L; Sun H; Mo R; Zhang C
Biomaterials; 2015 Dec; 73():284-95. PubMed ID: 26426537
[TBL] [Abstract][Full Text] [Related]
6. Poly(ethylene glycol)-block-poly(ε-caprolactone)-and phospholipid-based stealth nanoparticles with enhanced therapeutic efficacy on murine breast cancer by improved intracellular drug delivery.
He X; Li L; Su H; Zhou D; Song H; Wang L; Jiang X
Int J Nanomedicine; 2015; 10():1791-804. PubMed ID: 25784805
[TBL] [Abstract][Full Text] [Related]
7. Antibody conjugated PLGA nanoparticles for targeted delivery of paclitaxel palmitate: efficacy and biofate in a lung cancer mouse model.
Karra N; Nassar T; Ripin AN; Schwob O; Borlak J; Benita S
Small; 2013 Dec; 9(24):4221-36. PubMed ID: 23873835
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of a paclitaxel-binding polymeric micelle for efficient breast cancer therapy.
Xiang J; Wu B; Zhou Z; Hu S; Piao Y; Zhou Q; Wang G; Tang J; Liu X; Shen Y
Sci China Life Sci; 2018 Apr; 61(4):436-447. PubMed ID: 29572777
[TBL] [Abstract][Full Text] [Related]
9. Construction of paclitaxel-loaded poly (2-hydroxyethyl methacrylate)-g-poly (lactide)-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine copolymer nanoparticle delivery system and evaluation of its anticancer activity.
Ma X; Wang H; Jin S; Wu Y; Liang XJ
Int J Nanomedicine; 2012; 7():1313-28. PubMed ID: 22419875
[TBL] [Abstract][Full Text] [Related]
10. The pharmacokinetics of oral lonidamine in breast and lung cancer patients.
Newell DR; Mansi J; Hardy J; Button D; Jenns K; Smith IE; Picollo R; Catanese B
Semin Oncol; 1991 Apr; 18(2 Suppl 4):11-7. PubMed ID: 2031191
[TBL] [Abstract][Full Text] [Related]
11. CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer.
Swaminathan SK; Roger E; Toti U; Niu L; Ohlfest JR; Panyam J
J Control Release; 2013 Nov; 171(3):280-7. PubMed ID: 23871962
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile.
Rafiei P; Haddadi A
Int J Nanomedicine; 2017; 12():935-947. PubMed ID: 28184163
[TBL] [Abstract][Full Text] [Related]
13. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer.
He Z; Huang J; Xu Y; Zhang X; Teng Y; Huang C; Wu Y; Zhang X; Zhang H; Sun W
Oncotarget; 2015 Dec; 6(39):42150-68. PubMed ID: 26517524
[TBL] [Abstract][Full Text] [Related]
14. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
15. Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 2. In vivo distribution and tumor localization studies.
Shenoy D; Little S; Langer R; Amiji M
Pharm Res; 2005 Dec; 22(12):2107-14. PubMed ID: 16254763
[TBL] [Abstract][Full Text] [Related]
16. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W
Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697
[TBL] [Abstract][Full Text] [Related]
17. Folate Modified Long Circulating Nano-Emulsion as a Promising Approach for Improving the Efficiency of Chemotherapy Drugs in Cancer Treatment.
Song B; Wu S; Li W; Chen D; Hu H
Pharm Res; 2020 Nov; 37(12):242. PubMed ID: 33188481
[TBL] [Abstract][Full Text] [Related]
18. Active and passive tumor targeting of a novel poorly soluble cyclin dependent kinase inhibitor, JNJ-7706621.
Danhier F; Ucakar B; Magotteaux N; Brewster ME; Préat V
Int J Pharm; 2010 Jun; 392(1-2):20-8. PubMed ID: 20226846
[TBL] [Abstract][Full Text] [Related]
19. Folic Acid and Poly(ethylene glycol) Decorated Paclitaxel Nanocrystals Exhibit Enhanced Stability and Breast Cancer-Targeting Capability.
Zhao J; Du J; Wang J; An N; Zhou K; Hu X; Dong Z; Liu Y
ACS Appl Mater Interfaces; 2021 Mar; 13(12):14577-14586. PubMed ID: 33728919
[TBL] [Abstract][Full Text] [Related]
20. A novel paclitaxel-loaded poly(epsilon-caprolactone)/Poloxamer 188 blend nanoparticle overcoming multidrug resistance for cancer treatment.
Zhang Y; Tang L; Sun L; Bao J; Song C; Huang L; Liu K; Tian Y; Tian G; Li Z; Sun H; Mei L
Acta Biomater; 2010 Jun; 6(6):2045-52. PubMed ID: 19969111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
